The Online Investor
Allarity Therapeutics Inc (ALLR)

Allarity Therapeutics is a biopharmaceutical company developing therapeutic candidates together with its proprietary DRP® companion diagnostics. Co.'s lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors and vascular endothelial growth factor receptor for the treatment of third line renal cell carcinoma in patients. Co.'s second therapeutic candidate is stenoparib and Co. is developing this candidate for the treatment of ovarian cancer. Co.'s third candidate is IXEMPRA® (ixabepilone), a selective microtubule inhibitor, which has been shown to interfere with cancer cell division.
Company Name: 
Allarity Therapeutics Inc
Website: 
www.allarity.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree ALLR Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Allarity Therapeutics Inc (ALLR) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.